Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer

Immune checkpoint inhibitor&ndash
based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell&ndash
mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.